Table 3.

Bayesian model outputs

Parameter	Caspofungin	Liposomal amphotericin B	Differencea
Analysis of the original head-to-head trial
NNT for one patient to be harmed	–	12 (95% CI 9–17)	n. a.
Additional stay per treated patient per NNT for one patient to be harmed
Bootstrap calculation; days	–	0.48 (95% CI 0.14–0.88)	n. a.
Cost per additional stay per patient per day due to amphotericin B-related nephrotoxicity
At direct cost of €626 per day	–	€298 (95% CI €89–€554)	n. a.
Total cost at cost per day of hospital stay of €626
Drug cost (incl. 19% VAT)	€5,700	€5,092	€608
Incremental cost due to nephrotoxicity	-	€298 (95% CI €89– €554)	−€298 (95% CI −€554–−€89)
./. Supplementary reimbursement	€5,151b	€4,745c	−€406
Cost	€549	€645 (95% CI €436–€901)*	−€96 (95% CI −352–113)d

^aCost of caspofingin./.cost of L-AmB

^bSupplementary reimbursement ZE 39.12

^cSupplementary reimbursement ZE 43.16

^dIn favor of caspofungin. Probability that total difference is ≤€0 is 79% (see Fig. 2).